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particular, recurrence sites were categorized 
into local, renal (ipsilateral or contralateral) 




The records were reviewed of 814 patients 
with a mean follow-up of 75.6 months. UISS 
risk categories were distributed as follows: 
high-risk (HR) 17.2%, intermediate-risk (IR) 
51.6% and low-risk (LR) 31.2%. Disease-free 
survival rates at 5 years were 63.9%, 88.3% 









respectively. The disease recurred in 193 
patients (23.7%), at distant sites (73.0% of 
recurrences), locally (11.9%), in the 
contralateral kidney (10.9%) and in the 
ipsilateral kidney (4.1%). There was a 
significant correlation between UISS category 









recurrences, whereas there was no correlation 





















The prognostic accuracy and applicability of 
the UISS for distant and local recurrences is 
confirmed, whereas renal relapses have an 
independent course. A follow-up scheme 
tailored to the recurrence patterns observed 




renal cell carcinoma, recurrence, follow-up, 




To define a follow-up protocol based on 
the University of California Los Angeles 
Integrated Staging System (UISS) for patients 





The clinical records of patients treated with 
radical surgery for N0/NXM0 RCC and 





24 months in disease-free patients) were 
reviewed retrospectively from 1399 patients 
surgically treated for renal neoplasms 
between 1983 and 2005. Each case was 
assigned a UISS risk category; recurrence 




Of patients undergoing radical nephrectomy 
for non-metastatic RCC at diagnosis, 20–40% 
have disease recurrence during the follow-up 
[1]. Even though the biological behaviour of 
renal neoplasms remains unpredictable, the 
connection between prognosis and several 
tumour- and host-related risk factors, when 
considered both individually and combined 
within integrated staging systems, has been 
widely confirmed [2]. The University of 
California Los Angeles Integrated Staging 
System (UISS) [3], amongst others, stands out 
for its accuracy, user-friendliness and 
reproducibility, and for use with external data 
sets [4].
The purpose of the present retrospective 
study was to verify the time and patterns of 
the recurrences recorded in many patients 
with N0/NXM0 RCC who had been treated 
and monitored at one institution, and thus to 




Between January 1983 and December 2005, 
the data from 1399 consecutive patients 
treated surgically for parenchymal renal 
neoplasm and monitored through periodic 
follow-up studies (every 6 months for the 
first 2 years and then every year) including a 
physical examination, laboratory tests (kidney 
and liver function tests, blood tests, serum 
protein electrophoresis, calcaemia and 
alkaline phosphatase) and targeted chest 
(X-ray or CT) and abdomen (ultrasonography 
or CT) examinations were recorded in a 
dedicated database. Further abdominal CT 
was scheduled for 4 months after surgery to 
all patients treated by conservative surgery, to 
exclude disease persistence.
An anatomical and pathological evaluation 
was carried out over the follow-up by two 
uropathologists; the 1997 TNM staging 
method was used [5] and tumour histological 
types were reassigned according to 
Heidelberg classification [6], with cytonuclear 
grading defined according to the Fuhrman 
system [7].
We reviewed retrospectively the records of 
patients treated radically (with no clinical or 
histological evidence of disease persistence) 
for N0/NXM0 RCC at diagnosis and monitored 




24 months in 
disease-free patients.
By integrating stage, grade and Eastern 
Cooperative Oncology Group (ECOG) 
performance status [8], the UISS risk category 
for non-metastatic carcinoma was assigned 
as low-, intermediate- or high-risk (LR, IR and 
HR) [3] (Table 1). Recurrence time and sites 
were then recorded and categorized 
according to the following nomenclature: 
operated kidney; contralateral kidney; local 
(lumbar fossa, retroperitoneal lymph nodes, 
neoplastic caval thrombosis); distant (chest, 
abdomen, superficial, bone, brain or 
disseminated).
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The significance of differences between 




-test, and between nominal variables using 
the chi-square test; survival was analysed 
using the Kaplan–Meier method and 
differences were estimated using the log-rank 




 values were used 









We selected the records of 814 patients (mean 
age 61.7 years, range 20.6–85.5; male-to-
female ratio 1.5 : 1) who had either 
conservative surgery (158) or nephrectomy 
(656) for N0/NXM0 RCC at diagnosis. The 
most frequent tumour histological types were 






, range) overall follow-up 
was 75.6 (48.3, 4–296) months and 
82.9 (47.9) months for currently disease-free 
patients. There were no significant differences 
in mean follow-up between UISS risk 
categories (LR 76.1 months, IR 79.2, HR 
68.4). Table 2 shows the UISS stage 
distribution.
The disease progressed in 193 patients (23.7% 
of 814); the cause-specific survival at 5 years 
was 96.5%, 88.3% and 63.9% for LR, IR 








 0.001). In particular, 53.6% (75), 21.9% 
(92) and 10.2% (26) patients at HR, IR and LR 
developed a recurrence in the site and at the 
time shown in Table 3. The difference in 
disease progression rates among the three 









 0.001). There was a significant 
correlation between UISS stage and risk of 








 0.001) recurrence, 


















 0.898) kidney, with prevailing 
proportions in lower risk categories. UISS 
staging correlated with mean time to 
recurrence, although it was statistically 
insignificant (LR 53.5 months, IR 36.1, HR 
30.0). Figure 1a–c shows the recurrence 
distribution of isolated thoracic, abdominal 
(abdominal metastases, renal recurrences, 
local recurrences) and bone recurrences over 
time in each risk group.
There was a significantly lower risk of 
recurrence in general in patients treated with 
nephron-sparing surgery than nephrectomy 








 0.001). Nevertheless, 
when data were stratified based on UISS stage 

























Likewise, the mean time to recurrence, at 36.7 
and 36.0 months, respectively, was similar for 
the two groups.
In 95.3% of patients who had recurrent 
disease there was a conventional RCC; in 
particular, recurrences affected 25.4%, 12.0% 
and no patients with conventional, tubulo-
papillary and chromophobic RCC, respectively. 
Data stratification based on UISS stage 
showed no statistically significant differences 
in progression rates between conventional 


























Of 193 recurrences, 133 were treated with 
curative intent; in particular, 93 patients were 
treated with surgery, 31 with chemo-
immunotherapy and nine with radiotherapy. 
Disease recurrence was detected at a still 
asymptomatic stage in 147 patients (76.2%); 
50 showed no further signs of disease within 
a mean follow-up of 53.8 months after 
recurrence, 48 of them had reported no 
symptoms at diagnosis, while 49 of them had 
been treated with surgery. In general, patients 
whose recurrence was treated had a higher 
survival rate than had untreated patients 
(survival at 24 months after recurrence was 








 0.001). Patients with 
asymptomatic recurrences had a significantly 
higher survival rate from disease recurrence 
(survival at 24 months after recurrence was 








 0.001). Finally, patients 
with an isolated recurrence had better 
survival rates than those with multiple-site 
recurrences (survival at 24 months after 












Despite the dramatic increase in the rate of 
early diagnoses in last two decades, RCC 
remains the urological malignancy associated 







LR pT1 G1-2 ECOG 0






pT3 G1 or ECOG 0













The UISS stage distribution 
and type of surgery selected 






Conservative 2 (1.3) 70 (44.3) 86 (54.4)
Radical nephrectomy 138 (21.0) 350 (53.4) 168 (25.6)




Recurrence sites and time, as a percentage of asymptomatic patients, and the distribution of 
different types of recurrence in UISS risk groups (percentages in bold are calculated only for patients with 






months Asymptomatic LR IR HR
Operated kidney 8 (4.1) 23.4 100.0 11.6 5.4 0
Contralateral kidney 21 (10.9) 71.8 95.2 30.1 10.1 4.0
Local recurrence 23 (11.9) 26.4 69.5 3.9 7.6 20.0
Distant recurrence 141 (73.0) 29.5 73.0 53.8 76.1 76.0
Abdomen
 




















 21 (14.9) 24.1 52.4 14.3 11.4 19.3
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explained by the lack of effective systemic 
treatments for advanced disease, which is 
detected at diagnosis in 20–30% of patients 
or during the follow-up in 20–40% of those 
with organ-confined disease at diagnosis [1].
After initial recommendations for intensive, 
indiscriminate follow-up [10], tailored 
surveillance protocols based on TNM staging 
were defined, with minimal requirements for 
low but also for more advanced stages, 
considering the lack of successful treatments 
for recurrences [11–13]. More recently, the 
development of staging systems integrating 
several individually acknowledged prognostic 
factors has led to the definition of groups of 
patients with a better diversified recurrence 
risk [14–22] and to the creation of different 
follow-up protocols. Following the review 
of 559 patients with non-metastatic disease 
(but 40 N+ cases), stratified according to 
UISS stage, system developers recently 
recommended the first surveillance scheme 
based on clinical evidence [23].
The UISS integrates clinical factors commonly 
recorded (stage, grade and ECOG score) and 
so, besides having a tried and tested 
prognostic value, it can be easily applied also 
to external data sets, as was shown recently 
[4,24]. Moreover, comprehensive case reviews 
[19] showed the treatment-independent 
prognostic role played by several host-related 
factors in metastatic patients (performance 
status, weight loss, lactate dehydrogenase, 
haemoglobin level, calcium, sedimentation 
rate, etc.), and the use of a performance 
indicator (ECOG score) to stratify also non-
metastatic cases certainly supports the 
validity of the UISS, confirming the prognostic 
role of symptoms at diagnosis.
Likewise, in the present study, the UISS was 
used for 814 consecutive patients treated 
with radical surgery for non-metastatic RCC 
(N0/NXM0) at a University centre other than 
the centre where the system was designed. 
All patients were monitored through an 





 24 months in disease-free patients, 
80 months on average) follow-up protocol.
The data presented confirm that radical 
surgery for non-metastatic RCC is associated 
with a considerable rate of recurrence 
(23.7%), which mainly takes the form of 
distant metastases (73% of recurrences). The 
high proportion of asymptomatic and isolated 
recurrences would seem to indicate the good 
sensitivity of the surveillance approach 
applied. However, the large majority of 
patients who never had progression were 
excessively monitored, causing a concomitant 
increase in costs.
Also in our experience, the use of the UISS led 
to the appropriate prognostic discrimination 
of patients, as shown by the statistically 
significant differences resulting from the 
comparison between recurrence and disease-
free survival rates. Therefore, we confirm that 
the system is fully applicable to external data 
sets, with recurrence rates comparable with 




 [23], even though 
in our experience the survival rates were 
generally higher and differences between LR 
and IR patients significant but not so marked.
There was a substantial correlation between 
UISS category and the risk of local and distant 
recurrences, and with time to recurrence, 
which was shorter for the HR and IR groups. 
Conversely, there was no correlation between 
UISS stage and risk of renal recurrences, 
which were more frequent in the LR and IR 
groups. The rare event of recurrences in 
kidneys treated with conservative surgery was 
always in the first years of follow-up and 
should be attributed to underestimated 
multifocality or to technical and surgical 
factors, which are less related to the factors 
considered by the staging system. As to 
isolated recurrences in the contralateral 
kidney, the present long mean latency 
(71.8 months, range 7–291) suggests the 
potential development of a second 
independent neoplasm, which should not be 
considered a true ‘disease recurrence’. 
However, renal recurrences might also be 
related to previous or contemporary 
metastatic disease at other sites (17 cases in 
the present study, mean latency 41 months, 
range 8–121), which would otherwise indicate 
the potential metastatic nature of the second 
renal neoplasm. Probably only by comparing 
the tumour genome of the two neoplasms 
could these two conditions be differentiated 
to direct the therapy (systemic vs local) and 
follow-up.
Unlike other validated prognostic systems, e.g. 




 [16], the UISS 
does not rely on the tumour histological type. 
In our experience, chromophobic RCCs had an 
extremely favourable prognosis and we think 
that they should be managed as for LR cases, 
with the sole aim of preventing the effects 
of an incorrect histological diagnosis. 
Conversely, the differences between 
conventional and papillary RCC were not 
significant once the UISS was applied, and we 
think that this distinction should not be 
included.
Recurrence time and site distribution (Fig. 1 
and Table 3) show that the LR group had a 
low risk of abdominal recurrence, with a 
prevalence of renal recurrence, and a very low 
risk of thoracic metastasis. By contrast, the IR 
and HR groups had a risk, respectively, that 
was higher for recurrence both in the 
abdomen, usually with distant or local 
relapses, or in the chest. In the following 




The time distribution (marks representing the 
events of recurrence as percentiles on overall 
recurrences in each specific site) of: a, chest; b, 
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reduction in the risk, whereas fewer but 
significantly many recurrences, mainly in the 
chest and less in the abdomen, persisted for 
the IR and HR patients. After 10 years of 
follow-up recurrences were extremely rare 
and almost exclusively in the contralateral 
kidney. The follow-up scheme suggested 
(Table 4), which is based on these results, 
resembles the recommendations for the UISS 
[24]. We think that the additional follow-up 
after nephron-sparing surgery is unnecessary 
because the risk and time of recurrence is 
statistically equal to nephrectomy when the 
UISS is applied. Moreover, the rare event of a 
relapse in the operated kidney is prevented by 
the indication for abdominal studies in the 
first 5 years for all the UISS categories.
Because the present study was retrospective 
it is difficult to compare the risk-benefit 
ratios for each diagnostic method (X-ray, 
ultrasonography, CT, etc.) as a first-line survey. 
From our experience, we think it is reasonable 
to use more sensitive methods (thoracic-
abdominal CT) in the first 5 years of follow-
up, extensively for HR and less for IR patients. 
For LR patients, and after 5 years also for HR 
and IR patients, a chest X-ray and abdominal 
ultrasonography could direct second-line 
tests, their low cost and minimal invasiveness 
being proportionate to the reduced risk of 
recurrence.
Many studies confirm that a diagnosis of 
bone metastasis can be predicted from its 
symptoms, alkaline phosphatase values or the 
presence of extra bone metastases, making 
routine bone scintigraphy questionable, 
especially for LR patients and when the ECOG 
score is 0 [23]. Bone scanning was not a 
routine examination in our follow-up 
programme. Therefore, the diagnoses of 
isolated bone metastasis generally followed 
the appearance of symptoms or alterations in 
alkaline phosphatase levels, and they were 
rarely diagnosed when asymptomatic from 
bone anomalies on the chest or abdominal 
studies. Isolated bone metastases were 
detected in all three UISS categories (Fig. 1c) 
and therefore it can be supposed that a more 
extensive use of bone scintigraphy could help 
to estimate the real incidence of metastasis at 
this site and possibly anticipate the diagnosis. 
However, the fatal prognosis and the 
smallness of this group of patients make a 
consensus for this indication unlikely, and 
probably only a prospective evaluation could 
critically establish the real need for bone 
scanning.
Cerebral lesions were rare and developed only 
in IR or HR patients. For these categories the 
need for chest-abdominal CT could justify 
its occasional extension to the brain with 
no excessive increase in costs. Physical 
examinations and interviews with patients, 
together with serum and chemistry tests, 
should be included in long-term annual 
evaluation for all cases.
As an extensive recent review of previous 
reports [25] showed better results for survival 
when recurrences were asymptomatic, 
resectable and isolated, confirming that, given 
the lack of effective systemic therapies, early 
diagnosis can make the relapse salvageable 
and justify a careful follow-up for patients 
with RCC.




25% of cases, mainly as distant metastases, 
even after being treated radically. The results 
obtained with treatable recurrences and the 
high proportion of asymptomatic diagnoses 
support the need for a long-term follow-up, 
even though the lack of efficient systemic 
therapies means that prospects for treating 
patients with recurrence are rather poor. 
We confirm the prognostic accuracy and 
repeatability of the UISS for local and distant 
recurrences, whereas renal relapses were 
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LR Thoracic study every 30 months
and abdominal study yearly
Thoracic and abdominal
study every 30 months
Abdominal study every
5 years
IR Thoracic and abdominal
study every 6 months
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